

20 January 2022

## Usage of Biosimilar Medications in last 3 months re Adalimumab

I am investigating the usage of Biosimilar medications. Could you please provide the number of patients treated (for any condition) in the last 3 months with the following drugs: Adalimumab (any brand), Adalimumab (Amgevita), Adalimumab (Humira), Adalimumab (Hyrimoz), Adalimumab (Idacio), Adalimumab (Imraldi), Adalimumab (Hulio) and Adalimumab (Yuflyma).

Specialty	Adalimumab (any brand)	Adalimumab (Amgevita)	Adalimumab (Humira)	Adalimumab (Hyrimoz)	Adalimumab (Idacio)	Adalimumab (Imraldi)	Adalimumab (Hulio)	Adalimumab (Yuflyma)
<b>Dermatology</b>	203	39	43	0	0	121	0	0
<b>Rheumatology</b>	0	32	413	0	0	670	0	0
<b>Ophthalmology</b> * Paediatric Ophthalmology & Rheumatology		34*	37 56*			18		
<b>Immunology</b>	0	0	0	0	0	0	0	0
<b>Gastrointestinal*</b>	405	330 (includes Imraldi)	75			330 (includes Amgevita)		

*\*The way in which information is collected for Gastrointestinal does not distinguish by brand between Amgevita and Imraldi. To provide the information in the format requested would take more than 18 hours to retrieve. The Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit' as defined by the FOI Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.*